Drug Approval | August 12, 2021
SAB Biotherapeutics nonclinical data indicates SAB-185 neutralizes Delta and Lambda SARS-CoV-2 Variants
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Filing for WHO Emergency Use Authorisation this month
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
Subscribe To Our Newsletter & Stay Updated
